CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Secukinumab

Secukinumab

Last Updated: January 21, 2016

Result type: Reports

Project Number: SR0475-000

Product Line: Reimbursement Review

Generic Name: Secukinumab

Brand Name: Cosentyx

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: ankylosing spondylitis

Indications: Ankylosing spondylitis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 23, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions

Secukinumab

Files